Last reviewed · How we verify
Octreotide Injection
Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce blood flow to tumors.
Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and gastrointestinal peptides. Used for Acromegaly, Variceal bleeding in portal hypertension, Neuroendocrine tumors (carcinoid syndrome, VIPomas).
At a glance
| Generic name | Octreotide Injection |
|---|---|
| Also known as | Actide, Samarth, India, glucose |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the action of somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and blood vessels. This suppresses the release of growth hormone, insulin, glucagon, and other hormones, and reduces splanchnic blood flow. It is used to control symptoms of hormone-secreting tumors and to slow tumor growth in neuroendocrine malignancies.
Approved indications
- Acromegaly
- Carcinoid syndrome
- Variceal bleeding in portal hypertension
- Neuroendocrine tumors (gastroenteropancreatic)
- Thyroid storm
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
- Hyperglycemia
- Gallstone formation (cholelithiasis)
- Injection site pain
Key clinical trials
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Octreotide Microspheres for Preventing Pancreatic Fistula (PHASE3)
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (PHASE3)
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (PHASE2, PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octreotide Injection CI brief — competitive landscape report
- Octreotide Injection updates RSS · CI watch RSS
- Centre Hospitalier Universitaire, Amiens portfolio CI